In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ian Schofield

Executive Editor

Edinburgh, UK
Ian specialises in pharmaceutical regulatory affairs, mainly in the EU and the UK but also in Australia, New Zealand, Canada and certain African markets. His key areas of focus are clinical trials, market access, intellectual property issues, global regulatory alignment and pandemic preparedness. A modern languages graduate, he worked in the European travel industry before joining Scrip in 1985 as a reporter covering the French and Italian markets. He subsequently held posts including Deputy Editor of Scrip and Principal Analyst at Informa, before taking up his current position at the Pink Sheet. As well as writing news, features and analysis, Ian is part of the Ask the Analyst team that produces on-demand tailored reports for subscribers. His non-work interests include cycling, travel, paddleboarding and playing traditional Scottish music.

Latest From Ian Schofield

‘Vast Amount Of Valuable Input’ Leads Australia To Extend HTA Review

A second public consultation on the review of the HTA system will be held in January to February 2024 after more than 100 stakeholder responses were received during the first consultation earlier this year.

Australia Health Technology Assessment

Partnerships Are Key To Sustainable mRNA Vaccine Production In LMICs

Low- and middle-income countries need to have the know-how, capability and capacity to produce mRNA vaccines, from concept, design and testing through to manufacturing and registration, a conference heard this week.

International Middle East and Africa

EMA Expands Early Engagement With Patients & Health Professionals

On the back of a successful pilot of early consultations with patients, the European Medicines Agency is extending the initiative so that patient and health care professional groups can give valuable input in areas such as unmet needs, clinical trial endpoints and expectations for future treatments.

Europe Drug Review

The Opportunities & Challenges Of Local mRNA Vaccine Production In Africa

Building new local manufacturing facilities raises issues such as regulatory complexity, the supply of raw materials and what to do with “ever-warm” production sites outside health crisis situations, a conference heard this week.

Middle East and Africa Vaccines

New UK Investment Facility To Boost Horizon-Scanning For Pipeline Drugs

An updated UK PharmaScan platform is to be delivered within the first three years of the new voluntary drug pricing scheme, with companies agreeing to provide “timely, accurate and comprehensive information” for all their medicines in development.

Europe United Kingdom

Voluntary Vs Statutory: Pharma Firms Soon To Choose Between Two UK Pricing Schemes

The UK’s new voluntary drug pricing and access deal is a “paradigm shift” that will see companies paying different levels of rebates depending on their product mix, with higher payments on older medicines making headroom for growth in newer drugs, according to one lawyer.

Europe United Kingdom
See All
UsernamePublicRestriction

Register